BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

UCSF researchers found the cancer drugs letrozole and irinotecan may reverse Alzheimer's effects, reducing tau protein clumps ...

The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that ...

Alzheimer’s disease is a type of dementia, and there are more than 7 million Americans living with it. According to the ...

Loe said that while Fast Track status doesn’t guarantee PMN310 will succeed in future Phase II or III Alzheimer’s trials, it ...

Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.

As expected, there are restrictions on the use of Leqembi (lecanemab), which has been cleared for patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer ...

A new study has found that an experimental drug may delay the onset of Alzheimer’s-related dementia in people who are almost ...

GE HealthCare Technologies' market position, rising earnings, and improving financials make it an attractive investment opportunity. Read more on GEHC stock.